Prime Medicine Inc’s filing revealed that its 10% Owner ARCH Venture Partners XII, LLC acquired Company’s shares for reported $20.0 million on Feb 15 ’24. In the deal valued at $6.25 per share,3,200,000 shares were bought. As a result of this transaction, ARCH Venture Partners XII, LLC now holds 3,200,000 shares worth roughly $18.34 million.
Then, ARCH Venture Partners X, LLC bought 3,200,000 shares, generating $20,000,000 in total proceeds. Upon buying the shares at $6.25, the 10% Owner now owns 3,200,000 shares.
Before that, NELSEN ROBERT bought 3,200,000 shares. Prime Medicine Inc shares valued at $20,000,000 were divested by the Director at a price of $6.25 per share. As a result of the transaction, NELSEN ROBERT now holds 3,200,000 shares, worth roughly $18.34 million.
TD Cowen initiated its Prime Medicine Inc [PRME] rating to a Buy in a research note published recently. A number of analysts have revised their coverage, including Wedbush’s analysts, who began to cover the stock in early April with a ‘”an Outperform”‘ rating. Stifel also remained covering PRME and has decreased its forecast on January 16, 2024 with a “Hold” recommendation from previously “Buy” rating. Citigroup started covering the stock on December 08, 2023. It rated PRME as “a Neutral”.
Price Performance Review of PRME
On Friday, Prime Medicine Inc [NASDAQ:PRME] saw its stock fall -1.38% to $5.73. Over the last five days, the stock has lost -0.35%. Prime Medicine Inc shares have fallen nearly -35.33% since the year began. Nevertheless, the stocks have fallen -54.67% over the past one year. While a 52-week high of $17.20 was reached on 02/27/24, a 52-week low of $5.47 was recorded on 04/05/24. SMA at 50 days reached $7.28, while 200 days put it at $9.35. A total of 0.51 million shares were traded, compared to the trading of 0.59 million shares in the previous session.
Levels Of Support And Resistance For PRME Stock
The 24-hour chart illustrates a support level at 5.64, which if violated will result in even more drops to 5.54. On the upside, there is a resistance level at 5.84. A further resistance level may holdings at 5.95. The Relative Strength Index (RSI) on the 14-day chart is 34.19, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.43, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 84.31%. Stochastics %K at 17.76% indicates the stock is a buying.
The most recent change occurred on October 09, 2023 when BMO Capital Markets began covering the stock and recommended ‘”an Outperform”‘ rating along with a $19 price target.
